Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

William R. Burns

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3049-4377; OpenAlex author ID A5101769952. Sources: OpenAlex.

Their work

Papers
37 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
151
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: 3 papers · 2021: 6 papers · 2022: 9 papers · 2023: 6 papers · 2024: 7 papers · 2025: 4 papers

Papers 37

  1. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  2. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  3. Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf196↗
  4. Distinct response to IL-1β blockade in liver- and lung-specific metastasis mouse models of pancreatic cancer with heterogeneous tumor microenvironments. Co-author DOI 10.1186/s40164-025-00607-w↗
  5. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  6. Sociodemographic variation in the utilization of minimally invasive surgical approaches for pancreatic cancer. Co-author DOI 10.1016/j.hpb.2024.07.403↗
  7. Clinical and pathological factors associated with survival in patients with pancreatic cancer who receive adjuvant therapy after neoadjuvant therapy: A retrosp… Co-author DOI 10.1016/j.surg.2024.01.008↗
  8. Clinical Relevance of Cancerization of Ducts in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002326↗
  9. Poor Prognostic Factors in Long-Term Survivors of Resected Pancreatic Ductal Adenocarcinoma: An International, Multicenter Cohort Study. Co-author DOI 10.1097/sla.0000000000006539↗
  10. Targeting heterogeneous tumor microenvironments in pancreatic cancer mouse models of metastasis by TGF-β depletion. Co-author DOI 10.1172/jci.insight.182766↗
  11. Development of a Composite Score Based on Carbohydrate Antigen 19-9 Dynamics to Predict Survival in Carbohydrate Antigen 19-9-Producing Patients With Pancreati… Co-author DOI 10.1200/po.24.00193↗
  12. Oncologic resection of pancreatic cancer with isolated liver metastasis: Favorable outcomes in select patients. Last author DOI 10.1002/jhbp.1303↗
  13. Tailoring Adjuvant Chemotherapy to Biologic Response Following Neoadjuvant Chemotherapy Impacts Overall Survival in Pancreatic Cancer. Co-author DOI 10.1007/s11605-022-05476-w↗
  14. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with r… Co-author DOI 10.1038/s41467-023-39196-9↗
  15. Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000000200↗
  16. Surgical Decision-Making in Pancreatic Ductal Adenocarcinoma: Modeling Prognosis Following Pancreatectomy in the Era of Induction and Neoadjuvant Chemotherapy. Co-author DOI 10.1097/sla.0000000000004915↗
  17. A Delay in Adjuvant Therapy Is Associated With Worse Prognosis Only in Patients With Transitional Circulating Tumor Cells After Resection of Pancreatic Ductal … Co-author DOI 10.1097/sla.0000000000005710↗
  18. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients trea… Co-author DOI 10.1002/cam4.4527↗
  19. Obstructive sleep apnea predicts pathologic response to neoadjuvant therapy in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/mco2.184↗
  20. Accurate Nodal Staging in Pancreatic Cancer in the Era of Neoadjuvant Therapy. Co-author DOI 10.1007/s00268-021-06410-y↗
  21. Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy. Co-author DOI 10.1007/s00268-022-06667-x↗
  22. Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. Co-author DOI 10.1016/j.surg.2021.10.015↗
  23. The Impact of the COVID-19 Pandemic on Multidisciplinary Clinics: A High-Volume Pancreatic Cancer Center Experience. Co-author DOI 10.1067/j.cpradiol.2022.05.001↗
  24. Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response. Co-author DOI 10.1158/1078-0432.ccr-21-4165↗
  25. RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/po.21.00404↗
  26. Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10663-1↗
  27. Ovarian Metastasis from Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s00268-021-06209-x↗
  28. Reliable Detection of Somatic Mutations for Pancreatic Cancer in Endoscopic Ultrasonography-Guided Fine Needle Aspirates with Next-Generation Sequencing: Impli… Co-author DOI 10.1007/s11605-021-05078-y↗
  29. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. Co-author DOI 10.1016/j.canlet.2020.10.039↗
  30. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy. Co-author DOI 10.1016/j.jamcollsurg.2020.11.018↗
  31. Periadventitial dissection of the superior mesenteric artery for locally advanced pancreatic cancer: Surgical planning with the "halo sign" and "string sign". Co-author DOI 10.1016/j.surg.2020.08.031↗
  32. An Aggressive Approach to Locally Confined Pancreatic Cancer: Defining Surgical and Oncologic Outcomes Unique to Pancreatectomy with Celiac Axis Resection (DP-… Co-author DOI 10.1245/s10434-020-09201-2↗
  33. Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jamcollsurg.2020.06.019↗
  34. Mesoportal bypass, interposition graft, and mesocaval shunt: Surgical strategies to overcome superior mesenteric vein involvement in pancreatic cancer. Co-author DOI 10.1016/j.surg.2020.07.054↗
  35. Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000004200↗
  36. Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiolo… First author DOI 10.1245/s10434-017-5810-x↗
  37. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Co-author DOI 10.1089/hum.2013.209↗

Closest collaborators

The 25 strongest of 151 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Richard Andrew Burkhart · 26 shared papers, 2020–2025 · strength 3.48
  2. Jin Peng He · 26 shared papers, 2020–2025 · strength 3.31
  3. Kelly J. Lafaro · 20 shared papers, 2020–2025 · strength 2.82
  4. Ammar A. Javed · 19 shared papers, 2020–2025 · strength 2.47
  5. Christopher Lee Wolfgang · 16 shared papers, 2020–2025 · strength 2.01
  6. Joseph R. Habib · 14 shared papers, 2020–2025 · strength 1.93
  7. Lei Zheng · 11 shared papers, 2021–2025 · strength 1.43
  8. Ding Ding · 11 shared papers, 2021–2023 · strength 1.42
  9. Jun Yu · 11 shared papers, 2020–2024 · strength 1.40
  10. Christopher L. Wolfgang · 10 shared papers, 2021–2023 · strength 1.33
  11. Christopher R. Shubert · 8 shared papers, 2022–2024 · strength 1.21
  12. Benedict Kinny‐Köster · 9 shared papers, 2020–2024 · strength 1.20
  13. Amol Kumar Narang · 8 shared papers, 2021–2023 · strength 0.92
  14. Ralph H. Hruban · 7 shared papers, 2021–2024 · strength 0.88
  15. Michael J. Wright · 7 shared papers, 2021–2023 · strength 0.83
  16. Sami Shoucair · 6 shared papers, 2021–2023 · strength 0.80
  17. Daniel A. Laheru · 7 shared papers, 2020–2023 · strength 0.77
  18. Elliot K. Fishman · 7 shared papers, 2020–2022 · strength 0.75
  19. Matthew John Weiss · 5 shared papers, 2021–2023 · strength 0.61
  20. Ingmar Florin Rompen · 3 shared papers, 2024–2025 · strength 0.47
  21. Eun Ji Shin · 4 shared papers, 2021–2023 · strength 0.43
  22. Dung Thi Le · 4 shared papers, 2021–2023 · strength 0.43
  23. Ana De Jesus‐Acosta · 4 shared papers, 2021–2023 · strength 0.43
  24. Sophia Y. Chen · 2 shared papers, 2024–2025 · strength 0.41
  25. Heng‐Chung Kung · 2 shared papers, 2024–2025 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.